AlphaLiquid - Model Detect - Tumor-Informed, Hybrid-Capture NGS-Based Liquid Biopsy Test
From AlphaLiquid
AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets. By delivering exceptional detection levels (<0.005% LOD), AlphaLiquid® Detect provides clinically actionable information for relapse monitoring and adjuvant therapy guidance with a significant lead time over conventional imaging diagnostics.
-
Most popular related searches
Product Details
- Assay Type: Tumor tissue sequencing
- Targeted hybrid capture NGS based on proprietary HQS™ technology
- Sample Requirement: Tissue : FFPE (10μm x 10 sections) or FF
- Blood : >20mL of whole blood
- Targets: Customized panel of up to 1,000 targets
- Detected Alterations: SNVs and Indels
- Limit of Detection: 0.005% ~ 0.0005% ctDNA fraction
AlphaLiquid Detect Test Process
- Sequencing of tumor tissue and matched whole blood (optional)
- Design of bespoke panel including patient-specific biomarkers from tissue analysis and additional therapeutic targets of choice
- Longitudinal surveillance through serial liquid biopsy testing based on ultradeep targeted hybridization capture NGS to detect presence of ctDNA
Customer reviews
No reviews were found for AlphaLiquid - Model Detect - Tumor-Informed, Hybrid-Capture NGS-Based Liquid Biopsy Test. Be the first to review!